Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis
Table 2b. Recommendations for coadministering antiretroviral drugs with rifampin in children – 2013
| Antiretroviral drug regimen choices* |
Recommended change in dose of antiretroviral drug |
Recommended change in dose of rifampin |
Comments |
| “Super-boosted” lopinavir / ritonavir + 2 NRTIs |
Pediatric weight-adjusted dosing for lopinavir/ritonavir* (Kaletra™)PLUSadded ritonavir to reach mg to mg parity of lopinavir and ritonavir doses |
No change |
Preferred. |
| Zidovudine/lamivudine/abacavir |
None |
No change |
Alternative for children <3 years |
| Efavirenz + 2 NRTIs |
None |
No change |
Efavirenz AUC ↓ by 20-30% on average, though effect is highly variable.Alternative for children age >3 years.
Careful monitoring of virologic response; therapeutic drug monitoring of efavirenz levels if available |
* For pediatric dosing see: Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. August 11, 2011; pp 1-268. Available at http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdfpdf iconexternal icon.